About China Shineway Pharmaceutical Group

China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and trading of Chinese medicines. The company’s production capacity for injection products is 2 billion vials per annum. Its production capacity for soft capsule products is 3.5 billion capsules per annum. Product Portfolio Qing Kai Ling injection is an anti-viral medicine for treatment of viral diseases, including respiratory tract infection, viral hepatitis, cerebral haemorrhage and cerebral thrombosis. Shen Mai injection is used for treatment of coronary heart disease, viral myocarditis, and pulmonary heart disease. Shen Mai injection is used in clinical applications. Wu Fu Xin Nao Qing soft capsule is used for prevention and treatment of coronary heart disease and cerebral arteriosclerosis. Shu Xie Ning injection is used for treatment of cardio-cerebrovascular diseases. It is a Chinese medicine for treating cardio-cerebrovascular disease. Emerging Products: The company’s products under development include Huo Xiang Zheng Qi soft capsule – for prevention and treatment of heat stroke, stomach ache, nausea and diarrhea; Huang Qi injection – medicine for cardiovascular diseases and anti-viral – for treatment of viral myocarditis, heart malfunction, and hepatitis; and Qing Kai Ling soft capsule – for treatment of high fever, viral influenza, and respiratory tract infection. Pediatric Granule Series The company has a series of granule products for children infected by respiratory related diseases. History China Shineway Pharmaceutical Group Limited was incorporated in 2002.